The FDA lifted its clinical hold on Novavax's COVID-flu vaccine trial. The hold was due to unrelated safety concerns, allowing trial resumption. Novavax aims for growth with its combination shot ...

Novavax (NASDAQ:NVAX) shares climbed 12% premarket on Monday after the U.S. FDA lifted clinical hold on the investigational new drug application for the pharma firm’s COVID-19-Influenza ...

The U.S. Food and Drug Administration has put Novavax's trial of an experimental COVID-flu vaccine combination on hold after one person who received the shot reported nerve damage, the company ...

The Food and Drug Administration halted Novavax's trial of a combination vaccine for COVID and influenza, as well as a ...

The clinical hold does not impact the COVID-19 IND for Novavax’s COVID-19 vaccine. In April 2022, Novavax announced initial results from the Phase 1/2 trial of its CIC Vaccine.

Novavax Inc. (NASDAQ:NVAX) stock is trading lower on Wednesday. The FDA has placed a clinical hold on Novavax’s Investigational New Drug (IND) application for its COVID-19-influenza combination ...

The hold, which was made in response to a serious adverse event report, could impact the company’s plans to start a Phase 3 trial of a combination shot for COVID-19 and influenza.

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after a safety concern was found to be ...

The U.S. Food and Drug Administration has put on hold a trial of Novavax's COVID-influenza and its standalone flu vaccines after a participant who took the combination shot reported nerve damage ...

US News: The US Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines af.

Novavax (NVAX) shares surge 12% as FDA lifts clinical hold on COVID-19-Influenza Combination ... Novavax climbs as FDA lifts clinical hold on Covid, flu combo trials. Nov. 11, 2024 9:18 AM ET ...